Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  235.62
+1.74 (0.74%)
AAPL  285.33
+2.23 (0.79%)
AMD  216.66
-3.10 (-1.41%)
BAC  53.10
-0.14 (-0.26%)
GOOG  316.43
+1.31 (0.41%)
META  646.73
+5.86 (0.91%)
MSFT  490.44
+3.70 (0.76%)
NVDA  181.94
+2.02 (1.12%)
ORCL  201.98
+1.04 (0.52%)
TSLA  425.30
-4.84 (-1.13%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.